Volume 11 Supplement 1
7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Meeting abstracts
Publication of this supplement has been funded by the International congress on autoinflammatory disease (ISSAID) 2013. Abstracts are based on presentations made at the conference from ISSAID 2013.
7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID). Go to conference site.
Lausanne, Switzerland22-26 May 2013
Page 1 of 6
-
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A1
-
OR2-002 – The risk of FMF in MEFV heterozygotes
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A2 -
OR3-001 – RIP2 kinase is activated in Blau Syndrome and IBD
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A3 -
OR3-002 – Blau Syndrome cohort study: ocular outcome
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A4 -
P01-001 – Musculoskeletal sonography in FMF patients
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A5 -
P01-002 – Comparison between different colchicines responders
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A6 -
P01-003 – Bleeding disorder in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A7 -
P01-004 – MEFV genes and FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A8 -
P01-005 – Idiopathic uveitis and FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A9 -
P01-006 – MEFV mutation detection in Arabic patients
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A10 -
P01-007 – Evaluation of potential risk factors of Amyloidosis
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A11 -
P01-008 – FMF genotype-phenotype correlations in Germany
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A12 -
P01-009 – 2 years of colchicine IV in intractable FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A13 -
P01-010 – Anti-TNF agents in intractable FMF: four cases
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A14 -
P01-011 – Colchicine compliance and amyloidosis
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A15 -
P01-012 – Evaluation of autonomic function in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A16 -
P01-013 – Cochlear involvement in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A17 -
P01-014 – Subclinical atherosclerosis in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A18 -
P01-015 – Effect of Cochicine on cholesterol in FMF and BS
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A19 -
P01-016 – Decreased vitamin D levels in FMF patients
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A20 -
P01-017 – FMF presention with features of malignancy
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A21 -
P01-018 – An earliest diagnosis of FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A22 -
P01-019 – Anti-CCP antibodies are not associated with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A23 -
P01-020 – Starting time of inflammatory attacks in patients
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A24 -
P01-021 – Macrophage migration inhibitory factory in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A25 -
P01-022 – MEFV gene mutations registered to infevers
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A26 -
P01-023 – Leukocytoclastic vasculitis in a patient with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A27 -
P01-024 – Vascular risk assessment and MMP-3 gene in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A28 -
P01-025 – Decreased vitamin D levels in children with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A29 -
P01-026 – A case of FMF and hereditary coproporphyria
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A30 -
P01-027 – Normal HRV in colchicine-resistant FMF patients
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A31 -
P01-028 – MEFV mutation in Morrocan child wuth familial Mediterranean fever
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A32 -
P01-029 – Microscopic hematuria in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A33 -
P01-030 – Proteinuria in FMF – prediction of nephropathy type
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A34 -
P01-031 – Anakinra for colchicine resistant FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A35 -
P01-032 – Characterization of genetic-negative FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A36 -
P01-033 – Co-occurance of Crohn’s disease and FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A37 -
P01-034 – Cancer in FMF: a population based study Israel
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A38 -
P01-035 – Long-term IV colchicine in oral colchicines failure
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A39 -
P01-036 – Systemic amyloidosis presenting with amyloidoma
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A40 -
P01-037 – Genetic analysis practice prior to FMF diagnosis
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A41 -
P01-038 – QT and JT dispersion in children with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A42 -
P01-039 – Autonomic functions in children with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A43 -
P01-041 – Patient management and rare FMF symptoms
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A44 -
P01-042 – Joint involvement in Armenian children with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A45 -
P01-043 – Comparative characteristic of FMF and FMF with HSP
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A46 -
P01-044 – Uncommon manifestations of familial Mediterranean
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A47 -
P01-045 – Epilepsy in Armenian children with FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A48 -
P01-046 – Membrane aspects of Hemostasis disorders at ATYPIC
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A49 -
P01-047 – PH with right-sided heart failure in FMF
Citation: Pediatric Rheumatology 2013 11(Suppl 1):A50
Official journal of
Annual Journal Metrics
-
2022 Citation Impact
2.5 - 2-year Impact Factor
3.0 - 5-year Impact Factor
1.035 - SNIP (Source Normalized Impact per Paper)
0.732 - SJR (SCImago Journal Rank)2022 Speed
12 days submission to first editorial decision for all manuscripts (Median)
108 days submission to accept (Median)2022 Usage
901,346 downloads
750 Altmetric mentions